C
Cognition Therapeutics, Inc. (CGTX)
NCM – Real Time Price. Currency in USD
0.73
-0.35 (-32.40%)
At close: Mar 27, 2026, 4:00 PM EDT
0.74
+0.01 (2.00%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.73
-0.35 (-32.40%)
At close: Mar 27, 2026, 4:00 PM EDT
0.74
+0.01 (2.00%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
| Name | Position |
|---|---|
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer |
| Dr. Steven A. Weissman Ph.D. | VP & Head of CMC |
| Mr. Bobby Horn | Corporate Controller |
| Mr. John Brendan Doyle | Chief Financial Officer |
| Ms. Anita Cornet | Head of Quality |
| Ms. Lisa Ricciardi | CEO, President & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-02 | 8-K | tm267638d1_8k.htm |
| 2026-01-27 | 8-K | tm264096d1_8k.htm |
| 2025-12-18 | 8-K | tm2533712d1_8k.htm |
| 2025-11-06 | 10-Q | cgtx-20250930x10q.htm |
| 2025-09-15 | 8-K | tm2525997d1_8k.htm |
| 2025-08-28 | 8-K | tm2524576d2_8k.htm |
| 2025-08-26 | 8-K | tm2524388d1_8k.htm |
| 2025-08-07 | 8-K | tm2522152d2_8k.htm |
| 2025-06-20 | 8-K | tm2518439d2_8k.htm |
| 2025-06-03 | 8-K | tm2516905d1_8k.htm |